Medtronic engages former Senators Trent Lott and John Breaux to lobby on behalf of the company's $43 billion acquisition of Covidien and its subsequent move overseas.
Medtech titan Medtronic (NYSE:MDT) has a few heavy-hitters in its corner during its fight against anti-corporate inversion measures on Capitol Hill.
Despite the furor on Capitol Hill, lawmakers aren't likely to produce reform that will hinder Medtronic's $43 billion acquisition of Covidien, according to Morgan Stanley analysts.
Here's a look at some of the top regulatory stories for medical device companies this week: Report: Medtech M&A exits don't hinge on FDA approval; White House rails against Medtronic-style corporate inversions; Smith & Nephew CEO: We've been an M&A target for 10 years; More mega-merger talk from medtech giants; Baxter sheds vaccines biz for $635M
Covidien discloses details of the pending $43 billion acquisition by Medtronic, including who approached who and what Covidien chief Jose Almeida will do after handing the reins to Medtronic.
Democrats in the Senate and House push a measure to withhold federal contracts from companies that move their headquarters overseas to find better corporate tax rates.
A handful of Democrats in Congress are hoping to curb a corporate exodus by threatening to withhold federal contracts from firms that shift their headquarters overseas to benefit from lower tax rates.
The chiefs of Medtronic and Covidien hit the road to visit a slew of company sites and talk business as the medtech titans prepare to merge.
Medtronic's Omar Ishrak testing devices with with Gene Stellon, R&D VP at Covidien.
MassDevice.com looks at the internet chatter surrounding the medical device industry with some of most searched-for companies of the last month.
MassDevice.com looked at some of the most talked-about medical device companies, based on trends in U.S. Google searches for the last 30 days.